Drainage of Tuberculous Pleural Effusions

Tuberculous (TB) pleurisy can cause clinical symptoms and pleural fibrosis with resultant residual pleural thickening (RPT). Therapeutic thoracentesis or initial complete drainage in addition to anti-TB drugs have been tried to rapidly relieve dyspnea caused by effusion and to decrease the occurrence of RPT. However, contradictory results are reported without clear reasons. The researchers' hypothesis is that, in addition to anti-TB medications, early effective evacuation of inflammatory exudates with or without fibrinolytic agents may hasten resolution of pleural effusion, reduce the occurrence of RPT and finally improve long-term functional outcome in patients with TB pleurisy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tuberculous Pleurisy Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Mycobacterium Infections Pleural Diseases Pleural Effusion Respiratory Tract Diseases Respiratory Tract Infections Tuberculosis Tuberculosis, Extrapulmonary Tuberculosis, Pleural

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taipei Medical University Hospital

Taipei, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of tuberculous pleurisy

Exclusion criteria

History of invasive procedures directed into the pleural cavity
Recent severe trauma, hemorrhage, or stroke; bleeding disorder or anticoagulant therapy
Use of streptokinase in the previous 2 years
Lack of clinical symptoms caused by effusions

Treatment and study plan

Pigtail drainage

Procedure

Primary outcomes

Chest radiography, daily monitoring of the volume of fluid drained, the time needed for resolution of fever and dyspnea, and total amounts of fluid drained, and the length of chest drainage and hospitalization

Time frame: baseline, daily after treatment within admission

Secondary outcomes

Chest radiography and pulmonary function testing with spirometry

Time frame: At discharge and at 2, 4, 6, and 12 months

Sponsors and collaborators

Lead sponsor

Taipei Medical University Hospital

Other

Registry information

Important dates

Study start: 2003
Primary completion: 2005
Study completion: 2006
First posted: Sep 3, 2007
Registry last updated: Dec 30, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed